Clinical Trials Logo
  1. Home
  2. Central Nervous System Lymphoma
  3. NCT03690895
  4. Details
NCT03690895 Clinical Trial

Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Central Nervous System Lymphoma Clinical Trial

— LCPVIH  

Official title:
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03690895
Other study ID # NI_2015_2_AMR
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2015
Est. completion date October 1, 2016

Study information
Verified date September 2018
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.

Recruitment information / eligibility
Status Completed
Enrollment 51
Est. completion date October 1, 2016
Est. primary completion date October 1, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- HIV infection

- AIDS-related primary central nervous system lymphoma

- treated with at least one infusion of methotrexate and combine antiretroviral therapy

Exclusion Criteria:

- prior non-Hodgkin lymphoma

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Retrospective survival analysis
Kaplan-Meier model

Locations
Country Name City State
France Fondation Ophtalmologique A. de Rotchschild Paris

Sponsors (1)
Lead Sponsor Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Median duration of survival after diagnosis of lymphoma (years) At the time of systematic files review (jan 2014) - average follow-up 7 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516655 - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients Phase 2
Recruiting NCT05054426 - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Phase 3
Recruiting NCT02623010 - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04548648 - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Phase 2
Active, not recruiting NCT00293475 - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 1/Phase 2
Completed NCT03342586 - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT01011920 - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00967200 - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors N/A
Recruiting NCT03684980 - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Early Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04938297 - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma Phase 2
Recruiting NCT04792489 - DALY II USA/ MB-CART2019.1 for DLBCL Phase 2
Completed NCT01458730 - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00153530 - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Phase 4
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT05816746 - Decitabine and Anti-PD-1 in R/R DLBCL Phase 2
Recruiting NCT06031194 - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting NCT03962127 - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Recruiting NCT05114330 - Secondary Central Nervous System Lymphoma Registry - Charité